Article in International journal of molecular sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
14 authors.
Anna StasiakDepartment of Hormone Biochemistry, Faculty of Medicine, Medical University of Lodz, Żeligowskiego 7/9 Str., 90-752 Łódź, Poland.ORCID 0000-0002-2225-7312
Ewelina Honkisz-OrzechowskaDepartment of Technology and Biotechnology of Drugs, Faculty of Pharmacy, Jagiellonian University Medical College in Kraków, Medyczna 9 Str., 30-688 Kraków, Poland.ORCID 0000-0002-2046-4879
Zbigniew GajdaDepartment of Technology and Biotechnology of Drugs, Faculty of Pharmacy, Jagiellonian University Medical College in Kraków, Medyczna 9 Str., 30-688 Kraków, Poland.ORCID 0000-0002-2062-7818
Waldemar WagnerDepartment of Hormone Biochemistry, Faculty of Medicine, Medical University of Lodz, Żeligowskiego 7/9 Str., 90-752 Łódź, Poland.ORCID 0000-0003-1286-8360
Katarzyna Popiołek-BarczykDepartment of Neurochemistry, Maj Institute of Pharmacology, Polish Academy of Sciences, Smętna 12 Str., 31-343 Kraków, Poland.
Kamil J KuderDepartment of Technology and Biotechnology of Drugs, Faculty of Pharmacy, Jagiellonian University Medical College in Kraków, Medyczna 9 Str., 30-688 Kraków, Poland.ORCID 0000-0003-3077-5539
Gniewomir LataczDepartment of Technology and Biotechnology of Drugs, Faculty of Pharmacy, Jagiellonian University Medical College in Kraków, Medyczna 9 Str., 30-688 Kraków, Poland.ORCID 0000-0001-9247-2598
Michał JuszczakDepartment of Molecular Genetics, Faculty of Biology and Environmental Protection, University of Lodz, Pomorska 141/143 Str., 90-236 Łódź, Poland.ORCID 0000-0003-4055-6102
Katarzyna WoźniakDepartment of Molecular Genetics, Faculty of Biology and Environmental Protection, University of Lodz, Pomorska 141/143 Str., 90-236 Łódź, Poland.ORCID 0000-0001-6666-7973
Tadeusz KarczDepartment of Technology and Biotechnology of Drugs, Faculty of Pharmacy, Jagiellonian University Medical College in Kraków, Medyczna 9 Str., 30-688 Kraków, Poland.ORCID 0000-0003-4035-659X
Katarzyna SzczepańskaDepartment of Medicinal Chemistry, Maj Institute of Pharmacology, Polish Academy of Sciences, Smętna 12 Str., 31-343 Kraków, Poland.ORCID 0000-0002-6110-9400
Marta Jóźwiak-BębenistaDepartment of Pharmacology and Toxicology, Medical University of Lodz, Żeligowskiego 7/9 Str., 90-752 Łódź, Poland.ORCID 0000-0001-9032-1438
Katarzyna Kieć-KononowiczDepartment of Technology and Biotechnology of Drugs, Faculty of Pharmacy, Jagiellonian University Medical College in Kraków, Medyczna 9 Str., 30-688 Kraków, Poland.ORCID 0000-0002-6752-7443
Dorota ŁażewskaDepartment of Technology and Biotechnology of Drugs, Faculty of Pharmacy, Jagiellonian University Medical College in Kraków, Medyczna 9 Str., 30-688 Kraków, Poland.ORCID 0000-0001-8454-4440
Funding
Jagiellonian University Medical College in Kraków N42/DBS/000300; N42/DBS/000298; N42/DBS/000332Statutory activity of Medical University of Lodz, Poland 503/1-156-06/503-11-001the National Science Centre, Poland UMO-2019/35/D/NZ7/01042
6 · The paper itself
Abstract
The future of therapy for neurodegenerative diseases (NDs) relies on new strategies targeting multiple pharmacological pathways. Our research led to obtaining the compound AR71 [(E)-3-(3,4,5-trimethoxyphenyl)-1-(4-(3-(piperidin-1-yl)propoxy)phenyl)prop-2-en-1-one], which has high affinity for human H
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.